Docosahexaenoic acid (DHA)

Alternative Medicine Review

Volumn 14, Issue 4, 2009, Pages 391-399

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; PLACEBO;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN DEVELOPMENT; BREAST MILK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; COLORECTAL CANCER; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FETUS DEVELOPMENT; FETUS GROWTH; GESTATION PERIOD; HUMAN; HYPERTENSION; INFANCY; LIPID METABOLISM; NONHUMAN; PREGNANCY; PUERPERAL DEPRESSION; RECOMMENDED DRUG DOSE; REVIEW; VISUAL ACUITY;

ADULT; ALZHEIMER DISEASE; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CHILD; CHILD DEVELOPMENT; COGNITION; DEVELOPMENTAL DISABILITIES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INFANT NUTRITIONAL PHYSIOLOGICAL PHENOMENA; INFANT, NEWBORN; MATERNAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NERVOUS SYSTEM DISEASES; NUTRITIONAL REQUIREMENTS; OXIDATIVE STRESS; PREGNANCY;

EID: 74049136172     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. www.chemdex.org/chemistry-link/docosahexaenoic-acid-dha-cervonic-acid- omega-3-essential-fatty-acid [Accessed October 21, 2009]
2. http://www.martek.com/Products-and-Services/ Infant-Nutrition.aspx [Accessed October, 23, 2009]
3. Spector AA. Essentiality of fatty acids. Lipids 1999;34:S1-S3.
4. Singh M. Essential fatty acids, DHA and the human brain. Indian J Pediatr 2005;72:239-242.
5. Jumpsen J, Clandinin MT. Brain Development: Relationship to Dietary Lipid and Lipid Metabolism. Champaign, IL: AOCS Press; 1997.
6. Lim GR Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in aged Alzheimer mouse model. Neurosci 2005;25:3032-3040.
7. Hashimoto M, Tanabe Y, Fujii Y, et al. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 2005;135:549-555.
8. National Institute on Aging. DHA Phase 3 trial in Alzheimer's disease, http://clinicaltrials.gov/ct/ show/NCT00440050 [Accessed October 14, 2009]
9. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000;71:213S-223S.
10. Olsen SF, Hansen HS, Sorensen TI, et al. Intake of marine fat, rich in (n-3)-polyunsaturated fatty acids, may increase birthweight by prolonging gestation. Lancet 1986;2:367-369.
11. Olsen SF, Sorensen JD, Secher NJ, et al. Randomized controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 1992;339:1003-1007.
12. Woodman RJ, Mori TA, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 2003;26:253.
13. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acid have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-1094.
14. Mori TA, Bao DQ, Burke V, et al. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999;34:253-260.
15. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic, and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003;166:85-93.
16. Kato T, Hancock RL, Mohammadpour H, et al. Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 2002;187:169-177.
17. Schonberg SA, Lundemo AG, Fladvad T, et al. Closely related colon cancer cell lines display different sensitivity to polyunsaturated fatty acids, accumulate different lipid classes and downregulate sterol regulatory element-binding protein 1. FEBS J 2006;273:2749-2765.
18. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005;115;2774-2783.
19. Kim HY, Akbar M, Lau A, Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22:6n-3). Role of phosphatidylserine in antiapoptotic effect. J Biol Chem 2000;275:35215-35223.
20. Whelan J, Jahns L, Kavanagh K. Docosahexaenoic acid: measurements in food and dietary exposure. Prostaglandins Leukot Essent Fatty Acids 2009;81:133-136.
21. Lloyd-Still JD, Powers CA, Hoffman DR, et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients; a randomized, controlled study. Nutrition 2006;22:36-46.
22. Davis BC, Kris-Etherton PM. Achieving optimal essential fatty acid status in vegetarians: current knowledge and practical implications. Am J Clin Nutr 2003;78:640S-646S.
23. Arterburn LM, Oken HA, Bailey Hall E, et al. Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid. J Am Diet Assoc 2008;108:1204-1209.
24. van Houwelingen AC, Sorensen JD, Hornstra G, et al. Essential fatty acid status in neonates after fish-oil supplementation during late pregnancy. Br J Nutr 1995;74:723-731.
25. Otto SJ, van Houwelingen AC, Hornstra G. The effect of different supplements containing docosahexaenoic acid on plasma and erythrocyte fatty acids of healthy non-pregnant women. Nutr Res 2000;20:917-927.
26. Cunnane SC, Francescutti V, Brenna JT, Crawford MA. Breast-fed infants achieve a higher rate of brain and whole body docosahexaenoate accumulation than formula-fed infants not consuming dietary docosahexaenoate. Lipids 2000;35:105-111.
27. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992;120:S129-S138.
28. Hart SL, Boylan LM, Carroll SR, et al. Brief report: newborn behavior differs with docosahexaenoic acid levels in breast milk. J Pediatr Psychol 2006;31:221-226.
29. Drover J, Hoffman DR, Castaneda YS, et al. Three randomized controlled trials of early long-chain polyunsaturated fatty acid supplementation on means-end problem solving in 9-month-olds. Child Dev 2009;80:1376-1384.
30. Birch EE, Castaneda YS, Wheaton DH, et al. Visual maturation of term infants fed long-chain polyunsaturated fatty acid-supplemented or control formula for 12 mo. AmJ Clin Nutr 2005;81:871-879.
31. Birch EE, Hoffman DR, Castaneda YS, et al. A randomized controlled trial of long-chain polyunsaturated fatty acid supplementation of formula in term infants after weaning at 6 wk of age. Am J Clin Nutr 2002;75:570-580.
32. Hoffman DR, Birch EE, Castaneda YS, et al. Visual function in breast-fed term infants weaned to formula with or without long-chain polyunsaturates at 4 to 6 months: a randomized clinical trial. J Pediatr 2003;142:669-677.
33. Heiland IB, Smith L, Saarem K, et al. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. Pediatrics 2003;111:e39-e44.
34. Futterman S, Downer JL, Hendrickson A. Effect of essential fatty acid deficiency on the fatty acid composition, morphology, and electroretinographic response of the retina. Invest Ophthalmol 1971;10:151-156.
35. SanGiovanni JP, Berkey CS, Dwyer JT, Colditz GA. Dietary essential fatty acids, long-chain polyunsaturated fatty acids, and visual resolution acuity in healthy fullterm infants: a systematic review. Early Hum Dev 2000;57:165-188.
36. SanGiovanni JP, Parra-Cabrera S, Colditz GA, et al. Meta-analysis of dietary essential fatty acids and long-chain polyunsaturated fatty acids as they relate to visual resolution acuity in healthy preterm infants. Pediatrics 2000,405:6:1292-1298.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
38. Birch EE, Hoffman DR, Uauy R, et al. Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. Pediatr Res 1998;44:201-209.
39. Auestad N, Montalto MB, Hall RT, et al. Visual acuity, erythrocyte fatty acid composition, and growth in term infants fed formulas with long chain polyunsaturated fatty acids for one year. Ross Pediatric Lipid Study. Pediatr Res 1997;41:1-10.
40. Carlson SE, Ford AJ, Werkman SH, et al. Visual acuity and fatty acid status of term infants fed human milk and formulas with and without docosahexaenoate and arachidonate from egg yolk lecithin. Pediatr Res 1996;39:882-888.
41. Makrides M, Neumann M, Simmer K, et al. Are long-chain polyunsaturated fatty acids essential nutrients in infancy? Lancet 1995;345:1463-1468.
42. Makrides M, Simmer K, Goggin M, Gibson RA. Erythrocyte docosahexaenoic acid correlates with the visual response of healthy, term infants. Pediatr Res 1993;33:425-427.
43. Birch EE, Birch DG, Hoffman DR, Uauy RD. Dietary essential fatty acid supply and visual acuity development. Invest Ophthalmol Vis Sci 1992;33:3242-3253.
44. Birch E, Birch D, Hoffman D, et al. Breast-feeding and optimal visual development. J Pediatr Ophthalmol Strabismus 1993;30:33-38.
45. Courage ML, McCloy UR, Herzberg GR, et al. Visual acuity development and fatty acid composition of erythrocytes in full-term infants fed breast milk, commercial formula, or evaporated milk. J Dev Behav Pediatr 1998;19:9-17.
46. Innis SM, Akrabawi SS, Diersen-Schade DA, et al. Visual acuity and blood lipids in term infants fed human milk or formulae. Lipids 1997;32:63-72.
47. Jorgensen MH, Hernell O, Lund R et al. Visual acuity and erythrocyte docosahexaenoic acid status in breast-fed and formula-fed term infants during the first four months of life. Lipids 1996;31:99-105.
48. Innis SM, Nelson CM, Rioux MF, King DJ. Development of visual acuity in relation to plasma and erythrocyte omega-6 and omega-3 fatty acids in healthy term gestation infants. Am J Clin Nutr 1994;60:347-352.
49. Smithers LG, Gibson RA, McPhee A, Makrides M. Higher dose of docosahexaenoic acid in the neonatal period improves visual acuity of preterm infants: results of a randomized controlled trial. Am J Clin Nutr 2008;88:1049-1056.
50. Olsen SF, Joensen HD. High liveborn birth weights in the Faroes: a comparison between birth weights in the Faroes and in Denmark. J Epidemiol Community Health 1985;39:27-32.
51. Smuts CM, Huang M, Mundy D, et al. A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy. Obstet Gynecol 2003;101:469-479.
52. Otto SJ, de Groot RH, Hornstra G. Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prostaglandins Leukot Essent Fatty Acids 2003;69:237-243.
53. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys.J Lipid Res 1990;31:237-247.
54. Catalan J, Moriguchi T, Slotnick B, et al. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 2002;116:1022-1031.
55. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch Neurol 2006;63:1545-1550.
56. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-1408.
57. Ryan AS, Keske MA, Hoffman JR Nelson EB. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther 2009;16:183-192.
58. Forsyth JS, Willatts P, Agostoni C, et al. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: follow up of a randomised controlled trial. BMJ 2003;326:953.
59. Kato T, Kolenic N, Pardini RS. Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status. Nutr Cancer 2007;58:178-187.
60. van Beelen VA, Roeleveld J, Mooibroek H, et al. A comparative study on the effect of algal and fish oil on viability and cell proliferation of Caco-2 cells. Food Chem Toxicol 2007;45:716-724.
61. Lien EL. Toxicology and safety of DHA. Prostaglandins Leukot Essent Fatty Acids 2009;81:125-132.
62. Denomme J, Stark KD, Holub BJ. Directly quantitated dietary (n-3) fatty acid intakes in pregnant Canadian women are lower than current dietary recommendations, http://jn.nutrition.org/ cgi/content/abstract/135/2/206 [Accessed October 6, 2009]
63. Fleith M, Clandinin MT. Dietary PUFA for preterm and term infants; review of clinical studies. Crit Rev Food Sci Nutr 2005;45:205-229.
64. Koletzko B, Lien E, Agostoni C, et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008;36:5-14.